Diagnostic Significance of Detecting Dysgranulopoiesis in Chronic Myeloid Leukemia

American Journal of Clinical Pathology

Volumn 120, Issue 5, 2003, Pages 778-784

  Xu, Yin ^a   Dolan, Michelle M ^b   Nguyen, Phuong L ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Accelerated phase; Blast crisis; Chromosome 17p; Chronic myeloid leukemia; Dysgranulopoiesis

Indexed keywords

ADULT; ARTICLE; BLAST CELL CRISIS; CHROMOSOME 17P; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DYSGRANULOPOIESIS; FEMALE; HUMAN; LEUKOCYTE DISORDER; MALE; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

EID: 0242332135     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/P2QUGBB9NVWV4JUD     Document Type: Article

References (37)

1. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-293.
2. Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93-99.
3. Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550-554.
4. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343-3356.
5. Thijsen S, Schuurhuis G, van Oostveen J, et al. Chronic myeloid leukemia from basics to bedside. Leukemia. 1999;13:1646-1674.
6. Muehleck SD, McKenna RW, Arthur DC, et al. Transformation of chronic myelogenous leukemia: clinical, morphologic, and cytogenetic features. Am J Clin Pathol. 1984;82:1-14.
7. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
8. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999;340:1649-1660.
9. Gahn B, Haase D, Unterhalt M, et al. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia. 1996;10:946-951.
10. Merlat A, Lai JL, Sterkers Y, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion: a report on 25 cases. Leukemia. 1999;13:250-257.
11. Jary L, Mossafa H, Fourcade C, et al. The 17p-syndrome: a distinct myelodysplastic syndrome entity? Leuk Lymphoma. 1997;25:163-168.
12. Lai JL, Preudhomme C, Zandecki M, et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion: an entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia. 1995;9:370-381.
13. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107:76-94.
14. Sessarego M, Ajmar F. Correlation between acquired pseudo-Pelger-Hü et anomaly and involvement of chromosome 17 in chronic myeloid leukemia. Cancer Genet Cytogenet. 1987;25:265-270.
15. Vardiman JW, Brunning RD, Harris NL. Chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:20-26. World Health Organization Classification of Tumours.
16. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol. 1994;87:746-754.
17. Kennedy GA, Kay TD, Johnson DW, et al. Neutrophil dysplasia characterised by a pseudo-Pelger-Hüet anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases. Pathology. 2002;34:263-266.
18. Candido A, Rossi P, Menichella G, et al. Indicative morphological myelodysplastic alterations of bone marrow in overt AIDS. Haematologica. 1990;75:327-333.
19. d'Onofrio G, Mancini S, Tamburrini E, et al. Giant neutrophils with increased peroxidase activity: another evidence of dysgranulopoiesis in AIDS. Am J Clin Pathol. 1987;87:584-591.
20. Westhoff DD, Samaha RJ, Barnes A Jr. Arsenic intoxication as a cause of megaloblastic anemia. Blood. 1975;45:241-246.
21. Soenen V, Preudhomme C, Roumier C, et al. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome: analysis of breakpoints and deleted segments by fluorescence in situ. Blood. 1998;91:1008-1015.
22. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998;91:616-622.
23. Mitelman F. Catalog of Chromosome Aberrations in Cancer. 5th ed. New York, NY: Wiley-Liss; 1994:2748-2931.
24. Le Beau MM, Albain KS, Larson RA, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes No. 5 and 7. J Clin Oncol. 1986;4:325-345.
25. Fleischman EW, Prigogina EL, Volkova MA, et al. Correlations between the clinical course, characteristics of blast cells, and karyotype patterns in chronic myeloid leukemia. Hum Genet. 1981;58:285-293.
26. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. Am J Med. 1987;83:445-454.
27. Nakai H, Misawa S, Taniwaki M, et al. Prognostic significance of loss of a chromosome 17p and p53 gene mutations in blast crisis of chronic myelogenous leukaemia. Br J Haematol. 1994;87:425-427.
28. Hernandez-Boluda JC, Cervantes F, Costa D, et al. Blast crisis of Ph-positive chronic myeloid leukemia with isochromosome 17q: report of 12 cases and review of the literature. Leuk Lymphoma. 2000;38:83-90.
29. Ahuja H, Bar-Eli M, Advani SH, et al. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci U S A. 1989;86:6783-6787.
30. Kelman Z, Prokocimer M, Peller S, et al. Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood. 1989;74:2318-2324.
31. Foti A, Ahuja HG, Allen SL, et al. Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis. Blood. 1991;77:2441-2444.
32. Ahuja H, Bar-Eli M, Arlin Z, et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest. 1991;87:2042-2047.
33. Mori N, Wada M, Yokota J, et al. Mutations of the p53 tumour suppressor gene in haematologic neoplasms. Br J Haematol. 1992;81:235-240.
34. Peller S, Yona R, Kopilova Y, et al. Molecular alterations in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukemia. Genes Chromosomes Cancer. 1998;21:2-7.
35. Honda H, Ushijima T, Wakazono K, et al. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML. Blood. 2000;95:1144-1150.
36. Fenaux P, Jonveaux P, Quiquandon I, et al. p53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood. 1991;78:1652-1657.
37. Fioretos T, Strombeck B, Sandberg T, et al. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p 11 and is not associated with coding TP53 mutations. Blood. 1999;94:225-232.